Stuttgart - Delayed Quote EUR

Belite Bio Inc (D01.SG)

54.50

+1.50

+(2.83%)

At close: May 2 at 9:26:35 PM GMT+2

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City, Utah. The presentations will highlight base

GlobeNewswire 3 days ago

BLTE
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without any modification; trial completion expected Q4 2025 (including a three-month follow-up period)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with 406 subjects enrolledRaised $15 million in gross proceeds in a registered direct offering on February 5,

GlobeNewswire last month

BLTE
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 17, 2025, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of c

GlobeNewswire last month

BLTE
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, March 17, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the fourth quarter and full year ended December 31, 2024. Webcast

GlobeNewswire last month

BLTE
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Healthcare Conference being held on March 10-12, 2025, in Miami, FL. The Company will host a fireside chat on Monday, March 10, 2025, at 3:

GlobeNewswire last month

BLTE
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned interim efficacy analysis; trial completion expected by Q4 2025 (including a three-month follow-up period)Tinlarebant has been granted Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and the Pioneer Drug Designation in Japan fo

GlobeNewswire 2 months ago

BLTE
Belite Bio Announces Registered Direct Offering of $15 Million

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the purchase and sale of 258,309 American Depositary Shares (“ADSs”) and warrants to purchase

GlobeNewswire 2 months ago

BLTE
Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE)

Belite Bio, Inc ( NASDAQ:BLTE ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. 3 months ago

BLTE
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Fast Track designation indicates LBS-007’s potential in filling the unmet medical need of acute leukemiaLBS-007 is the Company’s investigational medicinal product for the treatment of acute leukemiaA Phase 1/2 trial in patients with relapsed or resistant acute leukemias is ongoingLBS-007, the Company’s lead asset, has been granted orphan drug designations for acute myeloid leukemia and acute lymphocytic leukemia by the U.S. FDA TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScienc

GlobeNewswire 5 months ago

6696.TWO

BLTE
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geographic atrophy (GA) subjects is ongoing with more than 280 subjects enrolledAppointed Hendrik P.N. Scholl, MD, MA, a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest natural history study of Stargardt disease, as Chief Medical OfficerInterim analysis from the pivo

GlobeNewswire 5 months ago

BLTE
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2024. Webcast Informatio

GlobeNewswire 5 months ago

BLTE
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in A

GlobeNewswire 5 months ago

BLTE
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will present data from its completed Phase II adolescent Stargardt disease trial at the American Academy of Ophthalmology Annual Meeting (AAO 2024) being held October 18-21, 2024,

GlobeNewswire 6 months ago

BLTE
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hendrik P.N. Scholl, MD, MA, Chief Medical Officer of Belite Bio, will participate in the “Ocular Drug Development” panel discussion at the Maxim Group 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 11:

GlobeNewswire 6 months ago

BLTE
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held September 24th and 25th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3ZHifQf The company presentations will be available 24/7 for 90 days. Sep

GlobeNewswire 7 months ago

AZN

AZNCF

BDOUF
Here's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 7 months ago

BLTE
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respo

GlobeNewswire 7 months ago

FPAFF

FPAFY

SSEZF
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

Phase 2/3 of the DRAGON II trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in approximately 60 adolescent STGD1 subjects across the U.S., U.K., and JapanPhase 1b of DRAGON II trial to evaluate pharmacokinetics and pharmacodynamics of Tinlarebant in Japanese subjects was recently completedTinlarebant granted Orphan Drug and Sakigake (Pioneer Drug) Designation in Japan for the treatment of STGD1Pivotal global Phase 3 trial of Tinlarebant in GA subjects (“PHOENIX”) is ongo

GlobeNewswire 7 months ago

BLTE
Belite Bio to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details for the presentations are as follows: H.C. Wainwright 26th Annual Global Investment Conference (New York, New York) Septem

GlobeNewswire 7 months ago

BLTE
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its bo

GlobeNewswire 7 months ago

BLTE

Performance Overview

Return	D01.SG	MSCI WORLD (^990100-USD-STRD)
YTD	-7.63%	+0.45%
1-Year	+45.33%	+10.81%
3-Year	+61.99%	+32.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Belite Bio Inc (D01.SG)

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

Belite Bio Announces Registered Direct Offering of $15 Million

Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE)

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

Here's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn Situation

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

Belite Bio to Participate in Three Upcoming Investor Conferences

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Performance Overview